Company Filing History:
Years Active: 2017-2022
Title: Im Sook Min: Innovator in Pharmaceutical Chemistry
Introduction
Im Sook Min is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target protein kinases. With a total of three patents to his name, his work is recognized for its potential impact on medical treatments.
Latest Patents
Among his latest patents is the invention of a 2,3-dihydro-isoindole-1-one derivative, which serves as a BTK kinase suppressant. This innovative compound is designed to treat, relieve, or prevent diseases caused by abnormal or uncontrolled activation of protein kinases. The patent outlines the compound's various forms, including pharmaceutically acceptable salts, esters, prodrugs, hydrates, solvates, and isomers. Additionally, it describes the compound's use in the manufacture of medicaments aimed at addressing these medical conditions.
Career Highlights
Im Sook Min is currently associated with Crystalgenomics, Inc., where he continues to advance his research and development efforts. His work is pivotal in creating pharmaceutical compositions that include his innovative compounds as active ingredients.
Collaborations
He collaborates with esteemed colleagues such as Yong Rae Hong and Jeong Eun Na, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Im Sook Min's contributions to pharmaceutical chemistry exemplify the importance of innovation in developing treatments for complex diseases. His work not only enhances our understanding of protein kinases but also paves the way for new therapeutic options.